TOKYO, Sept 25 (Reuters) - Japan's Eisai (4523.T) said on Monday its Alzheimer's treatment developed with Biogen (BIIB.O), Leqembi, was approved by the country's health ministry, making it the second nation after the United States to clear its use.
It can now be used in Japan as a treatment for slowing progression of mild cognitive impairment and mild dementia due to Alzheimer's disease.
